Background
Asthma is the most common chronic disease in childhood. According to the Center for Disease Control(CDC), nearly one in ten children are affected [
1]. The pathophysiology behind asthma is characterized by a Th2 inflammatory response which amounts to reversible airway hyper-responsiveness, inflammation, hypersecretion of mucus, and airway remodeling, all of which result in dynamic airway obstruction. During acute asthma exacerbations, which are the main causes of morbidity and mortality, there is an increase in symptoms usually due to known allergic (atopic) and non-allergic triggers. These exacerbations are usually the effect of viral illnesses commonly seen in the late fall to early winter months. Acute asthma treatment tends to be treated fairly quickly with the use of short-acting beta agonists (SABA) as well as short bursts of oral corticosteroids, frequently 3–5 days in duration. Unfortunately, these medications do not address the long-term control of asthma, or prevent hospitalizations. There are many available effective treatments to control baseline symptoms, including inhaled corticosteroids and leukotriene receptor antagonists [
1‐
3]. The utilization of these therapeutics, however, attack the underlying inflammation but cannot reverse the chronic airway remodeling that results from the continued inflammatory insult to the lungs.
Airway remodeling, as seen in chronic asthma, includes epithelial detachment, subepithelial fibrosis, increased smooth muscle mass, goblet cell hyperplasia, proliferation of blood vessels, and edema. Subepithelial fibrosis was first described by Roche and colleagues in 1989 where bronchial biopsies were taken in patients with asthma. Based on histology and immunohistochemistry, it has been shown that there can be a dense collagen network underneath the true basement membrane, including fibronectin, proteoglycans, and collagen types I and III [
2,
4]. The stimulus for airway remodeling is based on Th2 inflammation and chemotaxis of eosinophils. More specifically, eosinophils are produced in response to GM-CSF, IL4, and IL-13 and they produce pro-fibrotic mediators, especially TGF-beta [
5‐
9].
Fibroblasts are mesenchymal cells that are found in most tissues including lungs which produce extracellular matrix proteins and collagen that give tissues shape and structure. Normally, these fibroblasts support controlled wound healing in areas of epithelial damage. However, in the process of airway remodeling in asthma, inflammation and exposures to environmental triggers can cause excessive epithelial damage and subsequent uncontrolled fibroblast migration, which results in subepithelial fibrosis [
10,
11]. One of the important mediators in this process is IL-13 which stimulates fibroblast migration and invasion in asthma [
12].
Hyaluronan (HA) is also a major component of the ECM. Hyaluronan is a non-sulfated glycosaminoglycan (repeating disaccharide) polymer that is synthesized by multiple cell types including stromal cells, fibroblasts, epithelial cells, and smooth muscle cells [
13]. In the healthy lung, hyaluronan exists as high molecular mass (HMM HA), and is found within the peribronchial and perialveolar spaces. Within the ECM, HMM HA assists in cell movement, cushioning, and structural integrity [
13]. HMM HA is produced by three different isoforms of hyaluronic acid synthase (HAS1, HAS2, and HAS3) with HAS2 as the major isoform in human lung fibroblasts and is consistently elevated in fibroblasts that have been differentiated into myofibroblasts in asthmatic airways [
14,
15]. In the same study, it is of note that the asthmatic fibroblasts also increased collagen I and collagen III production.
Mesenchymal stem cells (MSCs) are a group of multipotent, self-renewing progenitor cells that can be derived from multiple tissue types, including bone marrow [
16], umbilical cord [
17], and compact bone [
18]. MSCs have been shown to differentiate in vitro into many different cell phenotypes including cells which make bone, cartilage, muscle, bone marrow, tendon/ligament, adipose tissue, and other connective tissue types [
16,
17,
19]. Previously, it has been shown that MSCs can produce IL-1RA, which blocks macrophage activation through IL-1 alpha and IL1-beta [
20‐
22], and TGF-beta, which suppresses macrophage and T cell activation [
23‐
25]. The ability of MSCs to produce significant amounts of cytokines and proteins is important in that these MSCs can alter the immune system by decreasing inflammation and promote wound healing. As such, MSC-based therapy represents a potential cure for asthma and is the focus of our study.
We hypothesized that fibroblasts modulate the amount of airway subepithelial fibrosis by producing collagen I, collagen III, and hyaluronan synthase 2. MSC therapy results in decreased expression of collagen and hyaluronan synthase 2 which would ultimately decrease subepithelial fibrosis and degenerative airway remodeling in chronic asthma.
Discussion
Chronic asthma is characterized by chronic inflammation and airway remodeling, which includes infiltration of inflammatory cells and abnormal accumulation of extracellular matrix (ECM). There are multiple components of the ECM with airway fibroblasts as the main cell type that producing this ECM them. Multiple studies have shown that in chronic asthma, there are increases in collagen synthesis and deposition as well hyaluronan deposition. The current treatment modalities for chronic asthma include inhaled corticosteroids, combination therapy of inhaled corticosteroids and long acting beta-adrenergic agonists, oral leukotriene receptor antagonists, and chronic oral steroids. MSCs offer another possible treatment modality that could possibly reverse or prevent chronic inflammation seen in chronic asthma and possibly offer improved side effect profiles than the current treatment regimens do not offered.
In our study, we use both in vitro and in vivo models. In the in vitro model, 3 T3 murine fibroblasts had increased levels of col. 1, col. 3 and HAs mRNA synthesis in response to GM-CSF stimulation as a model of increased airway remodeling and fibrosis (collagen expression) in response to inflammation and GM-CSF a relevant stimulus in asthma. In the in vivo model, OVA sensitized and challenged mice had increased ECM deposition as evidenced by increased trichrome staining. We were also able to show that OVA sensitized and challenged mice had increased soluble and insoluble collagen production which was decreased by hMSC infusion. Hyaluronan (HA) was increased in OVA sensitized and challenged mice and this was decreased by hMSC infusion. This study suggests a possible mechanism by which hMSCs decreased airway remodeling and fibrosis as evidenced by our in vitro and in vivo measurements of collagen production and deposition, ECM deposition, and HA production. Soluble and insoluble measures of collagen were not utilized in the in vitro 3 T3 assay since, the point of the outcome measure was to evaluate changes in complex tissues comprising more than just fibroblastic cells, which would not be representative of the soluble and insoluble measure.
One of the limitations in our study was the use of OVA protein which has not been shown to be pathogenic in human models. There are current studies, however, investigating sensitization with house dust mite antigens (Der P1 among others) and its ability to induce chronic inflammation and, subsequently, whether MSCs can reduce and possibly inhibit chronic inflammation [
31,
32]. The house dust mite antigen-sensitized murine model is likely to be more translational to human models.
In a recent study by Yilmaz et al. provided a review of remodeling and inflammation in pediatric asthma as well as possible therapeutic agents [
33]. The authors discussed remodeling of the airways and provide pathophysiologic mechanisms such as epithelial/subepithelial tissue rearrangement, sub-epithelial fibrosis, epithelial basement membrane thickening, myofibroblast hyperplasia, increased smooth muscle layer thickness, and neoangiogenesis [
33]. Chronic inflammation lead to excess fibroblast response which increased ECM deposition resulting in remodeling [
34,
35]. Our study provides additional insight into the underlying mechanism and also document that hMSCs might provide provided another therapeutic modality.
In conclusion, our study offers an insight into the possible mechanism of hMSCs therapy inhibiting chronic inflammation seen in a chronic asthma model induced by OVA sensitization. Future studies are needed to elucidate these mechanisms and to see whether these mechanisms are consistent in the house dust mite antigen model.
Conclusion
Chronic asthma is characterized by reversible airway hyper-responsiveness, inflammation, hypersecretion of mucus, and airway remodeling. Airway remodeling, as seen in chronic asthma, includes epithelial detachment, sub-epithelial fibrosis, increased smooth muscle mass, goblet cell hyperplasia, proliferation of blood vessels, and edema. The pathophysiology behind airway remodeling, especially sub-epithelial fibrosis, includes increased extracellular matrix deposition. This ECM deposition is made up of multiple types of components such as collagen I, collagen III, and the glycosaminoglycan hyaluronan. We were able to show a possible mechanism for hMSCs decreasing chronic inflammation in a cell-based and murine asthma model.
Acknowledgements
We would also like to thank: Jaime Aponte-Ortiz, Joseph Soltzberg, Emily Hedlund, Morgan Sutton, Lauren Auster, Christian Cronauer, Christiian van Heeckeren, Vainshnavi Ragayapuram, and David Fletcher for their technical support and assistance with this project.